Compare Adaptive Biotechnologies Corp (ADPT) vs Bit Digital Inc (BTBT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Bit Digital Inc — how do they compare? Adaptive Biotechnologies Corp trades at $25.05 (market cap $4.04B), while Bit Digital Inc trades at $1.46 (market cap $471.05M). The key difference: Adaptive Biotechnologies Corp is far larger — about 8.6× Bit Digital Inc's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Bit Digital Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | BTBT | |
|---|---|---|
Market Cap | $4.04B | $471.05M |
Sector | Health | Technology |
52-Week High | $25.45 | $4.22 |
52-Week Low | $12.30 | $1.23 |
Enterprise Value | $4.10B | $760.36M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $25.45, up 2.09% today, near its 52-week high. The stock shows bullish technical signals with support at $25 and resistance at $26. Revenue growth accelerated to $277M in 2025, though net losses persist. Recent news highlights a strategic separation of its MRD and Immune Medicine businesses, aiming to unlock value.
Outlook is cautiously optimistic with 65% analyst buy ratings and a $25.50 price target. Key opportunities include MRD segment profitability and separation benefits, while risks involve sustained losses, competitive pressures, and execution challenges in the business split.
BTBT trades at $1.485, up 14.23% in the last 24 hours, but remains in a bearish technical trend. The company reported a net loss of $80.32 million on $113.56 million revenue for 2025, with a negative net income margin of -145.45%. Recent earnings have missed expectations, though analyst consensus is a Buy with a $5.12 average price target.
The outlook is challenged by persistent losses and negative cash flow from operations, offset by strong financing activities. Key risks include execution on profitability and market volatility. The stock presents a high-risk opportunity contingent on the company's ability to reverse its negative earnings trend.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Bit Digital Inc
Bit Digital is a sustainability-focused digital asset production company. It primarily engages in Bitcoin mining and Ethereum staking while also providing high-performance computing (HPC) infrastructure for AI applications.
Read more on BTBT →
